Srikripa Devarakonda

Stock Analyst at Truist Securities

(2.88)
# 2,769
Out of 5,044 analysts
72
Total ratings
43.28%
Success rate
0.21%
Average return

Stocks Rated by Srikripa Devarakonda

Protagonist Therapeutics
Oct 28, 2025
Maintains: Buy
Price Target: $76$88
Current: $77.22
Upside: +13.96%
Scholar Rock Holding
Oct 20, 2025
Maintains: Buy
Price Target: $54$44
Current: $29.31
Upside: +50.12%
Viatris
Oct 15, 2025
Initiates: Buy
Price Target: $15
Current: $10.41
Upside: +44.09%
MBX Biosciences
Oct 15, 2025
Initiates: Buy
Price Target: $50
Current: $19.60
Upside: +155.10%
Madrigal Pharmaceuticals
Oct 15, 2025
Initiates: Buy
Price Target: $580
Current: $423.24
Upside: +37.04%
Terns Pharmaceuticals
Oct 15, 2025
Initiates: Buy
Price Target: $20
Current: $8.30
Upside: +140.96%
Kymera Therapeutics
Sep 30, 2025
Maintains: Buy
Price Target: $53$68
Current: $61.00
Upside: +11.48%
Regeneron Pharmaceuticals
Aug 11, 2025
Maintains: Buy
Price Target: $940$812
Current: $657.30
Upside: +23.54%
Incyte
Jul 30, 2025
Maintains: Hold
Price Target: $73$79
Current: $90.43
Upside: -12.63%
Arvinas
May 5, 2025
Downgrades: Hold
Price Target: $21$11
Current: $9.55
Upside: +15.18%
Maintains: Buy
Price Target: $210$199
Current: $149.07
Upside: +33.49%
Maintains: Buy
Price Target: $43$25
Current: $15.38
Upside: +62.55%
Maintains: Buy
Price Target: $1,029$1,038
Current: $821.27
Upside: +26.39%
Maintains: Buy
Price Target: $211$217
Current: $226.70
Upside: -4.28%
Maintains: Buy
Price Target: $36$32
Current: $24.41
Upside: +31.09%
Maintains: Buy
Price Target: $33$50
Current: $16.25
Upside: +207.69%
Upgrades: Buy
Price Target: $54
Current: $1.40
Upside: +3,757.14%
Maintains: Buy
Price Target: $18$15
Current: $8.75
Upside: +71.43%
Initiates: Buy
Price Target: $36
Current: $11.63
Upside: +209.68%
Maintains: Buy
Price Target: $86$70
Current: $62.26
Upside: +12.43%